50
Participants
Start Date
October 12, 2023
Primary Completion Date
November 4, 2027
Study Completion Date
April 4, 2028
Tislelizumab
Tislelizumab 200 mg will be administered every 3 weeks IV for a maximum of 2 years
RECRUITING
CHU Angers, Angers
RECRUITING
Hôpital Avicenne, Bobigny
RECRUITING
CHU Beaujon, Clichy
RECRUITING
Hôpital Michallon, Grenoble
RECRUITING
CHU La Croix Rousse, Lyon
RECRUITING
Hôpital Saint Joseph, Marseille
RECRUITING
Institut Paoli Calmette, Marseille
RECRUITING
CHU Saint Eloi, Montpellier
RECRUITING
Centre Eugene Marquis, Rennes
RECRUITING
CHRU Strasbourg, Strasbourg
UNICANCER
OTHER